NIH-funded research R01 grant

Coffee-derived metabolites that may boost survival after colorectal cancer

Official title: Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival

Funded at Harvard University D/b/a Harvard School of Public Health · NIH-11374108 · Data updated 2026-11-12

A biomarker-based trial will explore whether compounds from coffee and gut bacteria can improve outcomes for adults with colorectal cancer.

More Colorectal Cancer research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionHarvard University D/b/a Harvard School of Public Health
NIH-funded
Lab location1 site (Boston, United States)
Project startJune 2, 2022
Project endMay 31, 2027
Funding year2026
Award (this year)$664,676
NIH project number5R01CA263776-05
Project IDNIH-11374108 on NIH RePORTER

Who could benefit from this research

Could help

Adults 21 years or older with colorectal cancer who are receiving standard treatments and willing to participate in biomarker testing.

Less likely to help

Patients who do not drink coffee or cannot tolerate dietary components may not benefit from this specific approach.

What this research studies

This study tests if specific coffee-derived metabolites, shaped by the gut microbiome, are linked to better survival for adults with colorectal cancer. It will recruit participants and use a placebo-controlled design to see if these metabolites influence cancer progression and inflammation. The researchers will measure biomarkers in blood and tissue to understand mechanisms and potential benefits. If the approach works, it could guide dietary or microbiome-based strategies to support conventional cancer therapy.

Why it matters

Potential benefit: If successful, the findings could lead to dietary or microbial strategies that improve survival for people living with colorectal cancer.

How similar studies have gone: Observational data have suggested coffee-related associations with better outcomes, and this trial aims to test causality through a controlled design.

Where this research is happening

  • Harvard University D/b/a Harvard School of Public Health
    Boston, United States
    Active

Researchers

  • Principal investigator: Song, Mingyang — Harvard University D/b/a Harvard School of Public Health
  • Study coordinator: Song, Mingyang

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.